Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-868554 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | 200 mg |
| Name | Type | Description |
|---|---|---|
| PF-868554 | DRUG | 200 mg, Child-Pugh Class A |
Inclusion Criteria: * Male or females subjects of non-childbearing potential between the ages of 18 and 62 years of age, inclusive; * Body Mass Index (BMI) of approximately 18 to 35 kg/m2; and a total body weigh \>50 kg (110 lbs); Exclusion Criteria: * Subjects with Class C classification (Severe...
PF-868554 is an investigational small molecule being developed for the treatment of hepatitis C (HCV). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied to assess its safety, tolerability, and pharmacokinetics in patients with hepatic impairment.
PF-868554 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's potential as a treatment for hepatitis C.
PF-868554 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for its safety, tolerability, and pharmacokinetics in patients with hepatitis C and hepatic impairment.
PF-868554 has one completed Phase 1 clinical trial registered as NCT00651027. This study assessed the impact of hepatic impairment on the safety, tolerability, and pharmacokinetics of a single 200 mg dose of PF-868554 in 24 participants with hepatitis C. The trial was conducted in the United States.
PF-868554 is the only name provided for this investigational drug. It is a small molecule being developed by Pfizer for hepatitis C. No alternative names have been reported for this compound in the available information.